Financhill
Buy
54

MLTX Quote, Financials, Valuation and Earnings

Last price:
$38.65
Seasonality move :
26.17%
Day range:
$36.75 - $40.12
52-week range:
$31.42 - $58.26
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
5.63x
Volume:
745.3K
Avg. volume:
494.6K
1-year change:
-6.78%
Market cap:
$2.5B
Revenue:
--
EPS (TTM):
-$1.89

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
MLTX
MoonLake Immunotherapeutics
-- -$0.74 -- -248.49% $78.08
ACIU
AC Immune SA
$369.1K -$0.24 372.58% -22.94% $9.18
ADXN
Addex Therapeutics
$242.8K -- 2.35% -- $30.00
CRSP
CRISPR Therapeutics AG
$6M -$1.28 -96.36% -11.98% $82.50
NLSP
NLS Pharmaceutics
-- -- -- -- --
NVS
Novartis AG
$13B $2.17 8.26% 47.31% $112.37
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
MLTX
MoonLake Immunotherapeutics
$39.74 $78.08 $2.5B -- $0.00 0% --
ACIU
AC Immune SA
$1.66 $9.18 $166.7M -- $0.00 0% 5.10x
ADXN
Addex Therapeutics
$7.90 $30.00 $8.4M -- $0.00 0% 14.60x
CRSP
CRISPR Therapeutics AG
$36.14 $82.50 $3.1B -- $0.00 0% --
NLSP
NLS Pharmaceutics
$1.65 -- $6.3M -- $0.00 0% --
NVS
Novartis AG
$110.13 $112.37 $217.5B 17.23x $3.99 3.63% 4.17x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
MLTX
MoonLake Immunotherapeutics
-- 1.409 -- --
ACIU
AC Immune SA
-- 6.016 -- 1.50x
ADXN
Addex Therapeutics
-- 1.354 -- 4.36x
CRSP
CRISPR Therapeutics AG
-- 1.979 -- 21.97x
NLSP
NLS Pharmaceutics
-- 3.644 -- --
NVS
Novartis AG
43.44% 0.232 13.49% 0.50x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
MLTX
MoonLake Immunotherapeutics
-- -$49.6M -- -- -- -$48.6M
ACIU
AC Immune SA
-- -$21.5M -42.34% -42.34% -1916.67% -$21.3M
ADXN
Addex Therapeutics
-- -$719.5K 91.08% 91.08% -2836.3% -$713.3K
CRSP
CRISPR Therapeutics AG
-$57.5M -$148.4M -18.65% -18.65% -184.54% -$54.2M
NLSP
NLS Pharmaceutics
-- -- -- -- -- --
NVS
Novartis AG
$10.4B $4.7B 18.39% 30.96% 34.34% $2.2B

MoonLake Immunotherapeutics vs. Competitors

  • Which has Higher Returns MLTX or ACIU?

    AC Immune SA has a net margin of -- compared to MoonLake Immunotherapeutics's net margin of -1922.12%. MoonLake Immunotherapeutics's return on equity of -- beat AC Immune SA's return on equity of -42.34%.

    Company Gross Margin Earnings Per Share Invested Capital
    MLTX
    MoonLake Immunotherapeutics
    -- -$0.72 --
    ACIU
    AC Immune SA
    -- -$0.21 $107.6M
  • What do Analysts Say About MLTX or ACIU?

    MoonLake Immunotherapeutics has a consensus price target of $78.08, signalling upside risk potential of 96.47%. On the other hand AC Immune SA has an analysts' consensus of $9.18 which suggests that it could grow by 452.87%. Given that AC Immune SA has higher upside potential than MoonLake Immunotherapeutics, analysts believe AC Immune SA is more attractive than MoonLake Immunotherapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    MLTX
    MoonLake Immunotherapeutics
    11 1 0
    ACIU
    AC Immune SA
    3 0 0
  • Is MLTX or ACIU More Risky?

    MoonLake Immunotherapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison AC Immune SA has a beta of 1.617, suggesting its more volatile than the S&P 500 by 61.736%.

  • Which is a Better Dividend Stock MLTX or ACIU?

    MoonLake Immunotherapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. AC Immune SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. MoonLake Immunotherapeutics pays -- of its earnings as a dividend. AC Immune SA pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios MLTX or ACIU?

    MoonLake Immunotherapeutics quarterly revenues are --, which are smaller than AC Immune SA quarterly revenues of $1.1M. MoonLake Immunotherapeutics's net income of -$45.6M is lower than AC Immune SA's net income of -$21.2M. Notably, MoonLake Immunotherapeutics's price-to-earnings ratio is -- while AC Immune SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MoonLake Immunotherapeutics is -- versus 5.10x for AC Immune SA. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    MLTX
    MoonLake Immunotherapeutics
    -- -- -- -$45.6M
    ACIU
    AC Immune SA
    5.10x -- $1.1M -$21.2M
  • Which has Higher Returns MLTX or ADXN?

    Addex Therapeutics has a net margin of -- compared to MoonLake Immunotherapeutics's net margin of -2841.85%. MoonLake Immunotherapeutics's return on equity of -- beat Addex Therapeutics's return on equity of 91.08%.

    Company Gross Margin Earnings Per Share Invested Capital
    MLTX
    MoonLake Immunotherapeutics
    -- -$0.72 --
    ADXN
    Addex Therapeutics
    -- -$2.78 $13.1M
  • What do Analysts Say About MLTX or ADXN?

    MoonLake Immunotherapeutics has a consensus price target of $78.08, signalling upside risk potential of 96.47%. On the other hand Addex Therapeutics has an analysts' consensus of $30.00 which suggests that it could grow by 279.75%. Given that Addex Therapeutics has higher upside potential than MoonLake Immunotherapeutics, analysts believe Addex Therapeutics is more attractive than MoonLake Immunotherapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    MLTX
    MoonLake Immunotherapeutics
    11 1 0
    ADXN
    Addex Therapeutics
    0 0 0
  • Is MLTX or ADXN More Risky?

    MoonLake Immunotherapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Addex Therapeutics has a beta of 1.617, suggesting its more volatile than the S&P 500 by 61.657%.

  • Which is a Better Dividend Stock MLTX or ADXN?

    MoonLake Immunotherapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Addex Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. MoonLake Immunotherapeutics pays -- of its earnings as a dividend. Addex Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios MLTX or ADXN?

    MoonLake Immunotherapeutics quarterly revenues are --, which are smaller than Addex Therapeutics quarterly revenues of $62.3K. MoonLake Immunotherapeutics's net income of -$45.6M is lower than Addex Therapeutics's net income of -$1.8M. Notably, MoonLake Immunotherapeutics's price-to-earnings ratio is -- while Addex Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MoonLake Immunotherapeutics is -- versus 14.60x for Addex Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    MLTX
    MoonLake Immunotherapeutics
    -- -- -- -$45.6M
    ADXN
    Addex Therapeutics
    14.60x -- $62.3K -$1.8M
  • Which has Higher Returns MLTX or CRSP?

    CRISPR Therapeutics AG has a net margin of -- compared to MoonLake Immunotherapeutics's net margin of -106.6%. MoonLake Immunotherapeutics's return on equity of -- beat CRISPR Therapeutics AG's return on equity of -18.65%.

    Company Gross Margin Earnings Per Share Invested Capital
    MLTX
    MoonLake Immunotherapeutics
    -- -$0.72 --
    CRSP
    CRISPR Therapeutics AG
    -- -$1.58 $1.9B
  • What do Analysts Say About MLTX or CRSP?

    MoonLake Immunotherapeutics has a consensus price target of $78.08, signalling upside risk potential of 96.47%. On the other hand CRISPR Therapeutics AG has an analysts' consensus of $82.50 which suggests that it could grow by 128.28%. Given that CRISPR Therapeutics AG has higher upside potential than MoonLake Immunotherapeutics, analysts believe CRISPR Therapeutics AG is more attractive than MoonLake Immunotherapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    MLTX
    MoonLake Immunotherapeutics
    11 1 0
    CRSP
    CRISPR Therapeutics AG
    12 10 1
  • Is MLTX or CRSP More Risky?

    MoonLake Immunotherapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison CRISPR Therapeutics AG has a beta of 1.877, suggesting its more volatile than the S&P 500 by 87.729%.

  • Which is a Better Dividend Stock MLTX or CRSP?

    MoonLake Immunotherapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CRISPR Therapeutics AG offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. MoonLake Immunotherapeutics pays -- of its earnings as a dividend. CRISPR Therapeutics AG pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios MLTX or CRSP?

    MoonLake Immunotherapeutics quarterly revenues are --, which are smaller than CRISPR Therapeutics AG quarterly revenues of $35M. MoonLake Immunotherapeutics's net income of -$45.6M is higher than CRISPR Therapeutics AG's net income of -$136M. Notably, MoonLake Immunotherapeutics's price-to-earnings ratio is -- while CRISPR Therapeutics AG's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MoonLake Immunotherapeutics is -- versus -- for CRISPR Therapeutics AG. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    MLTX
    MoonLake Immunotherapeutics
    -- -- -- -$45.6M
    CRSP
    CRISPR Therapeutics AG
    -- -- $35M -$136M
  • Which has Higher Returns MLTX or NLSP?

    NLS Pharmaceutics has a net margin of -- compared to MoonLake Immunotherapeutics's net margin of --. MoonLake Immunotherapeutics's return on equity of -- beat NLS Pharmaceutics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    MLTX
    MoonLake Immunotherapeutics
    -- -$0.72 --
    NLSP
    NLS Pharmaceutics
    -- -- --
  • What do Analysts Say About MLTX or NLSP?

    MoonLake Immunotherapeutics has a consensus price target of $78.08, signalling upside risk potential of 96.47%. On the other hand NLS Pharmaceutics has an analysts' consensus of -- which suggests that it could grow by 14445.46%. Given that NLS Pharmaceutics has higher upside potential than MoonLake Immunotherapeutics, analysts believe NLS Pharmaceutics is more attractive than MoonLake Immunotherapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    MLTX
    MoonLake Immunotherapeutics
    11 1 0
    NLSP
    NLS Pharmaceutics
    0 0 0
  • Is MLTX or NLSP More Risky?

    MoonLake Immunotherapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NLS Pharmaceutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock MLTX or NLSP?

    MoonLake Immunotherapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NLS Pharmaceutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. MoonLake Immunotherapeutics pays -- of its earnings as a dividend. NLS Pharmaceutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios MLTX or NLSP?

    MoonLake Immunotherapeutics quarterly revenues are --, which are smaller than NLS Pharmaceutics quarterly revenues of --. MoonLake Immunotherapeutics's net income of -$45.6M is higher than NLS Pharmaceutics's net income of --. Notably, MoonLake Immunotherapeutics's price-to-earnings ratio is -- while NLS Pharmaceutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MoonLake Immunotherapeutics is -- versus -- for NLS Pharmaceutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    MLTX
    MoonLake Immunotherapeutics
    -- -- -- -$45.6M
    NLSP
    NLS Pharmaceutics
    -- -- -- --
  • Which has Higher Returns MLTX or NVS?

    Novartis AG has a net margin of -- compared to MoonLake Immunotherapeutics's net margin of 26.48%. MoonLake Immunotherapeutics's return on equity of -- beat Novartis AG's return on equity of 30.96%.

    Company Gross Margin Earnings Per Share Invested Capital
    MLTX
    MoonLake Immunotherapeutics
    -- -$0.72 --
    NVS
    Novartis AG
    76.31% $1.82 $67.9B
  • What do Analysts Say About MLTX or NVS?

    MoonLake Immunotherapeutics has a consensus price target of $78.08, signalling upside risk potential of 96.47%. On the other hand Novartis AG has an analysts' consensus of $112.37 which suggests that it could grow by 2.03%. Given that MoonLake Immunotherapeutics has higher upside potential than Novartis AG, analysts believe MoonLake Immunotherapeutics is more attractive than Novartis AG.

    Company Buy Ratings Hold Ratings Sell Ratings
    MLTX
    MoonLake Immunotherapeutics
    11 1 0
    NVS
    Novartis AG
    0 9 2
  • Is MLTX or NVS More Risky?

    MoonLake Immunotherapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Novartis AG has a beta of 0.603, suggesting its less volatile than the S&P 500 by 39.726%.

  • Which is a Better Dividend Stock MLTX or NVS?

    MoonLake Immunotherapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Novartis AG offers a yield of 3.63% to investors and pays a quarterly dividend of $3.99 per share. MoonLake Immunotherapeutics pays -- of its earnings as a dividend. Novartis AG pays out 63.85% of its earnings as a dividend. Novartis AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios MLTX or NVS?

    MoonLake Immunotherapeutics quarterly revenues are --, which are smaller than Novartis AG quarterly revenues of $13.6B. MoonLake Immunotherapeutics's net income of -$45.6M is lower than Novartis AG's net income of $3.6B. Notably, MoonLake Immunotherapeutics's price-to-earnings ratio is -- while Novartis AG's PE ratio is 17.23x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MoonLake Immunotherapeutics is -- versus 4.17x for Novartis AG. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    MLTX
    MoonLake Immunotherapeutics
    -- -- -- -$45.6M
    NVS
    Novartis AG
    4.17x 17.23x $13.6B $3.6B

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

What Is a Millionaire-Maker Stock?
What Is a Millionaire-Maker Stock?

From time to time, investors will run across the term…

5 Investors to Follow Other Than Warren Buffett
5 Investors to Follow Other Than Warren Buffett

There is no doubt that Warren Buffett is one of…

Is BYD a Threat To Tesla Shareholders?
Is BYD a Threat To Tesla Shareholders?

BYD (OTC:BYDDY) has rocketed to the top of China’s booming…

Stock Ideas

Buy
70
Is MSFT Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 37x

Sell
39
Is AAPL Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 32x

Buy
63
Is NVDA Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 40x

Alerts

Buy
99
DAVE alert for May 9

Dave [DAVE] is up 6.7% over the past day.

Buy
52
QDEL alert for May 9

QuidelOrtho [QDEL] is down 0.25% over the past day.

Buy
61
TPC alert for May 9

Tutor Perini [TPC] is up 8.44% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock